17.03.2023 • News

Lummus Wins Kazakhstan Butadiene Contracts

Lummus Technology has received a contract to supply multiple technologies to Butadiene LLP for a new petrochemical complex in Atyrau, Kazakhstan.

“We are grateful to be selected and provide multiple technologies and solutions to support Butadiene LLP’s growth and expansion,” said Lummus Technology’s president and CEO Leon de Bruyn. “Lummus’ integrated solutions can help grow the economic position of our customer as they execute this important project for Kazakhstan and its downstream industry.”

The scope of the contract includes the technology license and basic engineering for four process units, with Lummus providing its iC4 Catofin, Catadiene, CDMtbe processes and BASF’s butadiene extraction technology. Lummus has been licensing BASF’s butadiene extraction technology for over 30 years.

Once complete, the units will upgrade a mixed butanes feed to produce 85,000 t/y of isobutylene, 120,000 t/y of butadiene, and 40,000 t/y of methyl tert-butyl ether (MTBE). These products will feed Butadiene LLP’s new synthetic rubber production facility and supply the local Kazakhstan transportation fuels market.

Butadiene LLP is a joint venture that was set up by KazMunayGas and Russia’s Tatneft in November 2021 to produce a range of butadiene rubbers. Construction on the complex started last November and completion is scheduled for 2025.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Lummus Technology

5825 North Sam Houston Pkwy W #600
77086 Houston, TX
US

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.